Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

Ann Rheum Dis. 2020 Oct;79(10):1381-1382. doi: 10.1136/annrheumdis-2020-217706. Epub 2020 May 6.

Authors

Achille Aouba¹, Aurelie Baldolli², Loïk Geffray³, Renaud Verdon², Emmanuel Bergot⁴, Nicolas Martin-Silva⁵, Aurélien Justet⁴

Affiliations

¹ Department of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France [email protected].
² Department of Infectious Diseases, CHU Caen, Caen, France.
³ Department of Internal Medicine and Clinical Immunology, CH Lisieux, Lisieux, France.
⁴ Department of Pulmonology, CHU Caen, Caen, France.
⁵ Department of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France.

PMID: 32376597
DOI: 10.1136/annrheumdis-2020-217706

No abstract available

Keywords: antirheumatic agents; biological therapy; cytokines; interleukin 1 receptor antagonist protein; therapeutics.

Publication types

Letter

MeSH terms

Aged, 80 and over
Anti-Bacterial Agents / therapeutic use
Azithromycin / therapeutic use
Betacoronavirus
C-Reactive Protein / immunology
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / diagnostic imaging
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / physiopathology
Disease Progression
Enzyme Inhibitors / therapeutic use
Female
Hospitalization
Humans
Hydroxychloroquine / therapeutic use
Intensive Care Units
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Lung / diagnostic imaging
Male
Middle Aged
Pandemics
Pneumonia, Viral / diagnostic imaging
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / physiopathology
Respiratory Distress Syndrome / physiopathology
SARS-CoV-2
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome

Substances

Anti-Bacterial Agents
Enzyme Inhibitors
Interleukin 1 Receptor Antagonist Protein
Hydroxychloroquine
Azithromycin
C-Reactive Protein